-transparent.png){kind=logo}
We investigated the breakpoints of the bcr gene in 46 Ph1-positive CML cases by Southern blot analysis of bcr rearrangement, and in 17 CML cases by a combination of Southern blot analysis and RT-PCR. By Southern blot, the breakpoint was not identified on M-bcr in three CML cases, of which one case showed the P210-type bcr/abl transcript and two cases showed the ALL-type (P190-type) bcr/abl transcript with or without P210 transcript. Later two cases showed unique hematological profiles such as thrombocytosis, mild myelofibrosis, and relative resistance to alkylating agents. Therefore, the present study suggests that expression of the P190-type transcript may affect clinical and hematological findings in CML.
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
September 1999,
Leukemia research,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
May 2007,
Current hematologic malignancy reports,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
December 1993,
Experimental hematology,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
April 1997,
Blood,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
October 2011,
Hematology/oncology clinics of North America,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
January 2015,
Leukemia & lymphoma,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
May 2004,
Haematologica,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
April 2007,
Leukemia,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
March 2001,
Haematologica,
Y Kunieda, and
M Okabe, and
M Kurosawa, and
T Itaya, and
M Kakinuma, and
T Miyazaki
November 2017,
Clinical lymphoma, myeloma & leukemia,
